相似文献
1
Teaming up for CAR-T cell therapy.
Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676.
2
[The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].
Zhonghua Xue Ye Xue Za Zhi. 2022 Apr 14;43(4):265-271. doi: 10.3760/cma.j.issn.0253-2727.2022.04.001.
3
[Chimeric antigen receptor T-cell therapy for multiple myeloma].
Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189.
4
The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.
Biol Blood Marrow Transplant. 2019 Mar;25(3):e73-e75. doi: 10.1016/j.bbmt.2018.11.009. Epub 2018 Nov 16.
5
Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.
Bone Marrow Transplant. 2020 Nov;55(11):2215-2218. doi: 10.1038/s41409-020-0930-5. Epub 2020 May 9.
6
CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
Eur J Cancer. 2023 Mar;182:1-2. doi: 10.1016/j.ejca.2022.12.018. Epub 2022 Dec 29.
7
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
8
[Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Sheng Wu Gong Cheng Xue Bao. 2019 Dec 25;35(12):2339-2349. doi: 10.13345/j.cjb.190291.
9
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
Eur J Cancer. 2023 Jul;188:108-110. doi: 10.1016/j.ejca.2023.04.003. Epub 2023 May 23.
10
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
JAMA Oncol. 2022 Jun 1;8(6):823-824. doi: 10.1001/jamaoncol.2022.0319.
引用本文的文献
1
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.
Cancers (Basel). 2022 Oct 18;14(20):5108. doi: 10.3390/cancers14205108.
2
Adverse Renal Effects of Anticancer Immunotherapy: A Review.
Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.
3
Allogeneic Stem Cell Transplantation in Multiple Myeloma.
Cancers (Basel). 2021 Dec 23;14(1):55. doi: 10.3390/cancers14010055.
4
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.
Cancers (Basel). 2021 Aug 26;13(17):4320. doi: 10.3390/cancers13174320.
5
Novel immunotherapies in multiple myeloma - chances and challenges.
Haematologica. 2021 Oct 1;106(10):2555-2565. doi: 10.3324/haematol.2020.266858.
6
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402.
本文引用的文献
1
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.
2
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
3
Mechanisms of resistance to CAR T cell therapy.
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6.
4
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
5
Are CAR T cells better than antibody or HCT therapy in B-ALL?
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):16-24. doi: 10.1182/asheducation-2018.1.16.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.
Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.
8
Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670. doi: 10.1016/j.bbmt.2018.04.010. Epub 2018 Apr 19.
9
Current developments in immunotherapy in the treatment of multiple myeloma.
Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6.
10
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
Zotero 插件